Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04850638
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04850651
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 709
- Registration Number
- NCT04849000
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangzhou, China
SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04844125
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, China
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5274
- Registration Number
- NCT04842617
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT04842630
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 660
- Registration Number
- NCT04839016
A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 157
- Registration Number
- NCT04818333
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth.
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 187
- Registration Number
- NCT04812860
- Locations
- 🇨🇳
West China Hospital of Stomatology Sichuan University, Chengdu, Sichuan, China
HR021618 in Moderate to Severe Pain After Abdominal Surgery
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04811053
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
© Copyright 2024. All Rights Reserved by MedPath